BUSINESS● LOW2h ago · Sep 23, 2026, 11:27 AM
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Seeking Alpha Tech · global
Roivant's stock declined following Immunovant encountering a setback in clinical trials for its cutaneous lupus therapy. This news affects the companies involved and their investors.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS26m agoCox Capital launches tender offers for shares of Blackstone, BlackRock private credit funds at discount to NAVSeeking Alpha TechBUSINESS26m agoSchwab U.S. Broad Market ETF declares quarterly distribution of $0.0809Seeking Alpha Tech